Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01614067 · ClinicalTrials.gov registry record · Phase 4
Delayed Start to Ovarian Stimulation
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01614067 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT01614067, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.
Interventions
- DRUG Ganirelix acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01614067
The ClinicalTrials.gov registry entry for NCT01614067 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ganirelix acetate is the first listed.
NCT01614067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01614067 about?
NCT01614067 is a clinical study titled "Delayed Start to Ovarian Stimulation". In couples with infertility secondary to Diminished Ovarian Reserve, the investigators hypothesize that a delayed start (7 day) to ovarian stimulation with an GnRH antagonist (Ganirelix) will improve oocyte maturation and quality, and improve pregnancy outcomes.
What is the current status of trial NCT01614067?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2012-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01614067?
The interventions under investigation include: Ganirelix acetate (DRUG).
Who is sponsoring clinical trial NCT01614067?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.